医学信息
醫學信息
의학신식
MEDICAL INFORMATION
2014年
29期
28-28
,共1页
卵巢肿瘤%泡膜纤维瘤%病理学%放射疗法%药物疗法%预后
卵巢腫瘤%泡膜纖維瘤%病理學%放射療法%藥物療法%預後
란소종류%포막섬유류%병이학%방사요법%약물요법%예후
Ovarian neoplasms%Thecafibroma%Prognosis%Radiotherapy%Drug theragy%Pathology
目的：探讨卵巢泡膜纤维瘤的临床、病理特征、治疗和预后。方法回顾性分析了我院1996~2013年诊治的168例卵巢良、恶性卵泡膜纤维瘤的临床和病理资料。结果168例中，恶性卵泡膜纤维瘤16例；良性卵泡膜纤维瘤152例，其中18例伴细胞生长活跃。临床症状有腹部包块者104例（61.9%），其次为月经不调、阴道不规则出血、闭经、腹痛、不孕等；44例合并腹水，其中2例同时合并胸水；78例合并雌激素相关疾病，包括子宫内膜癌和内膜不典型增生各2例，子宫肌瘤、内膜复杂性增生、内膜息肉等。152例良性卵泡膜纤维瘤中，60例行 CA125检查，56例（33.3%）增高；18例伴细胞生长活跃的患者中，肿瘤侵犯周围组织和术后复发各2例，经手术和放射治疗，至今已无瘤生存11年和27年。16例恶性卵泡膜纤维瘤中，8例（Ⅰ-Ⅱb期各2例，复发4例）经积极手术后行放疗或化疗，除2例死于放射性肠瘘外，4例无癌生存10年以上，2例无癌生存3年。结论良性泡膜纤维瘤预后好，但应警惕伴细胞生长活跃者。恶性泡膜纤维瘤预后差，但积极手术后放疗或化疗，可明显延长生存时间。
目的：探討卵巢泡膜纖維瘤的臨床、病理特徵、治療和預後。方法迴顧性分析瞭我院1996~2013年診治的168例卵巢良、噁性卵泡膜纖維瘤的臨床和病理資料。結果168例中，噁性卵泡膜纖維瘤16例；良性卵泡膜纖維瘤152例，其中18例伴細胞生長活躍。臨床癥狀有腹部包塊者104例（61.9%），其次為月經不調、陰道不規則齣血、閉經、腹痛、不孕等；44例閤併腹水，其中2例同時閤併胸水；78例閤併雌激素相關疾病，包括子宮內膜癌和內膜不典型增生各2例，子宮肌瘤、內膜複雜性增生、內膜息肉等。152例良性卵泡膜纖維瘤中，60例行 CA125檢查，56例（33.3%）增高；18例伴細胞生長活躍的患者中，腫瘤侵犯週圍組織和術後複髮各2例，經手術和放射治療，至今已無瘤生存11年和27年。16例噁性卵泡膜纖維瘤中，8例（Ⅰ-Ⅱb期各2例，複髮4例）經積極手術後行放療或化療，除2例死于放射性腸瘺外，4例無癌生存10年以上，2例無癌生存3年。結論良性泡膜纖維瘤預後好，但應警惕伴細胞生長活躍者。噁性泡膜纖維瘤預後差，但積極手術後放療或化療，可明顯延長生存時間。
목적：탐토란소포막섬유류적림상、병리특정、치료화예후。방법회고성분석료아원1996~2013년진치적168례란소량、악성란포막섬유류적림상화병리자료。결과168례중，악성란포막섬유류16례；량성란포막섬유류152례，기중18례반세포생장활약。림상증상유복부포괴자104례（61.9%），기차위월경불조、음도불규칙출혈、폐경、복통、불잉등；44례합병복수，기중2례동시합병흉수；78례합병자격소상관질병，포괄자궁내막암화내막불전형증생각2례，자궁기류、내막복잡성증생、내막식육등。152례량성란포막섬유류중，60례행 CA125검사，56례（33.3%）증고；18례반세포생장활약적환자중，종류침범주위조직화술후복발각2례，경수술화방사치료，지금이무류생존11년화27년。16례악성란포막섬유류중，8례（Ⅰ-Ⅱb기각2례，복발4례）경적겁수술후행방료혹화료，제2례사우방사성장루외，4례무암생존10년이상，2례무암생존3년。결론량성포막섬유류예후호，단응경척반세포생장활약자。악성포막섬유류예후차，단적겁수술후방료혹화료，가명현연장생존시간。
Objective To study the clinical pathologic characteristics, treatment and prognostic factors of ovarian thecafibroma. Methods From 1986~2011, a total of 168 patients with benign and malignant thecafibroma were retrospectively analyzed. Results The reviewed diagnosis were 16 patients with malignant thecafibroma, 152 patients were benign thecafibroma . Eighteen of 152 patients with benign thecafibroma appeared cel proliferative activity. The mean age was 52years. The most frequent symptoms were abdominal-pelvic onasses (61.9%), metromenor hagia and abnormal vaginal bleeding, other symptoms were abdominal pain, infertility fol owed. fourty-four of 152 patients had ascites, only 2 patients with ascites and hydrothorax sinulaneously. Seventy-eight patients with diseases which associate with excessive extrogenic stimulation, including 2 endometrial adenocarcinoma and 2 endometrial dysplasia and other disease such as : myoma ; endmetial hyperplasia and polyp. One hundred and fifty-two patients with benign thecafibroma were evaluated blood serum CA125 , the CA125 were elevated in 56 of 60 patients . in 4 of 18 patients with cel proliferative activity , the tumors invaded adjacent tissues or relapsed , after received operation and pelvic radiotherapy , they are alive 11years and 27 years respectively .Among 16 patients with malignant thecafibroma , 8 patients without postoperation therapy or with non-standard chemotherapy died in 2 years postoperation , the other 8 patients received operation, postoprational radiotherapy or (and) chemotherapy , 2 of 8 patients died of ir adiation intestinal fistule 4 years later; Four patients are alive without disease more than 10 years , another two for 3 years . Conclusion Thea cel tumor of ovary have good prognosis , but we should pay at ention to thecafibroma with proliferative activity . The prognosis of malignant thecafibroma is poor, postoperative systemic chemotherapy or radiotherapy to the patients with malignant thecafibroma can improve their survival.
